News

• Sandoz launches ferumoxytol and pemetrexed generics
• US generic approvals for Acrux and Cipla
• Natco cancer generic approval and advances for Lannett asthma and diabetes products
• FDA approval for schizophrenia and HIV generics from Zydus Cadila and Lupin

Research

• Considerations for the evaluation of generic IUDs containing levonorgestrel
• Generic pharmaceutical policies in the MENA region
• The generics market in Brazil
• Laws on packaging, substitution and prescription of generics in Brazil

General

• New five-year medicines agreements in Australia
• Generics applications under review by EMA – July 2021
• A European pharmaceutical strategy promoting generics and biosimilars
• Use of generics increases during the COVID-19 pandemic in Mexico

News

• Bioeq submits application for ranibizumab biosimilar to FDA
• CuraTeQ submits application to EMA for pegfilgrastim biosimilar
• EMA recommends approval of two adalimumab biosimilars
• EC and FDA approval for first ranibizumab biosimilar Byooviz

Research

• Competition from biosimilars drives price reductions for biologicals in France
• Positive trial results for bevacizumab copies from Betta Pharmaceuticals and Biocad
• Candidate trastuzumab biosimilar AryoTrust
• Barriers to biosimilar prescribing incentives in Spain

General

• Potential biotech collaboration between India and Colombia
• Biosimilars approved in Paraguay
• Biosimilars approved in Cuba
• China approving more copy biologicals since new guidelines introduced

• Non‐Biological Complex Drugs
• Country Focus
• Guidelines

• Policies & Legislation
• Reports
• Pharma News

• Conferences
• Sponsored Links
• Sponsored Articles